SCHEMBL24089957

SCHEMBL24089957

CCN(CC)Cc1ccc(Nc2nc3ccc(F)cc3c(=O)n2-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 2/20 0.41
IDO2 Q6ZQW0 2/20 0.41
IDO1 P14902 1/20 0.41
P2RX3 P56373 1/20 0.39
POLB P06746 1/20 0.39
HTR7 P34969 2/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CG P48736 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
CASR P41180 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23065100 0.91 TDO2 (0.42) TDO2IDO2IDO1P2RX3POLB
SCHEMBL24090006 0.90 TDO2 (0.51) TDO2IDO2IDO1POLBHTR7
SCHEMBL29623221 0.88 PRMT5 (0.41)
SCHEMBL24089920 0.88 PRMT5 (0.41)
SCHEMBL29623172 0.86 TDO2 (0.44) TDO2IDO2IDO1POLBHTR7
SCHEMBL24090107 0.86 TDO2 (0.44) TDO2IDO2IDO1POLBHTR7
SCHEMBL29623155 0.84 TDO2 (0.50) TDO2IDO2IDO1POLBHTR7
SCHEMBL23045334 0.84 TDO2 (0.50) TDO2IDO2IDO1POLBHTR7
SCHEMBL24090084 0.83 BRAF (0.43) TDO2IDO2IDO1HTR7PIK3CG
SCHEMBL29746854 0.83 BRAF (0.43) TDO2IDO2IDO1HTR7PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114650986-A 2-aminoquinazolinone derivatives 住友制药株式会社 2022-06-21 CN claimed
CN-114650986-A 2-aminoquinazolinone derivatives 住友制药株式会社 2022-06-21 CN disclosed
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL TDO2 2059/4885IDO2 398/4885IDO1 386/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 TDO2 1774/4885IDO2 416/4885IDO1 592/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 TDO2 1774/4885IDO2 416/4885IDO1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.